Control Bionics Ltd. · ASX:CBL
Control Bionics — Shareholder Meeting (November 2025)
31 slides from Control Bionics's shareholder meeting presentation, Nov 25, 2025
Slide 1: FY2026 AGM Presentation
For personal use only Proven neurotech scaling multi-growth global markets FY2026 AGM PRESENTATION 25 NOVEMBER 2025 CON TROLBIO NIC S.C OM | ASX: CBL
Slide 2: Introduction
For personal use only Introduction Damian Lismore Non-Executive Interim Chairman
Slide 3: Acknowledgment of Country
Acknowledgment of Country I begin today by acknowledging the Gadigal people of the Eora Nation, Traditional For personal use only Custodians of the land on which we meet today, and pay my respects to their Elders past, present and emerging. I extend that respect to Aboriginal and Torres Strait Islan
Slide 4: Experienced leadership
LEADE RSHIP TE AM Experienced leadership For personal use only BOA RD • Over 20 years experience in accounting, auditing and finance roles in the United States and Australia • Previously held senior finance positions with multi- national ASX-listed and technology start-up entities Shannon Boothroyd
Slide 5: Voting Summary Report
Ag AUTOMIC ABN: 27 152 260 814 Voting Summary Report Control Bionics ted Annual General Meeting For personal use only Resolution 107,608,273 ‘Remuneration Report 97.91% 108,762,742 2 Re-elect Professor Robert Heard as « Director 98.03% 108,858,399 4 Re-elect Dr Stephanie Phillips as a Director 98.12
Slide 6: Resolution: Remuneration Report
Resolution 1 is as follows: For personal use only “That the Remuneration Report for the financial year ended 30 June 2025, as set out in the Directors’ Report be adopted.”
Slide 7: Resolution: Re-election of Professor Robert Heard
Resolution 2 is as follows: For personal use only “That Professor Robert Heard retires by rotation in accordance with Clause 60 of the Company’s Constitution and, being eligible for re-election, be re- elected as a Director.”
Slide 8: Resolution: Re-election of Dr Stephanie Phillips
Resolution 4 is as follows: For personal use only “That Dr Stephanie Phillips, having been appointed during the last year as a director pursuant to clause 59.1 of the Constitution, retires in accordance with Clause 59.2 of the Company’s Constitution and offers herself for election, be re-elected as
Slide 9: Resolution: Issue of Options to Jeremy Steele
Resolution 5 is as follows: For personal use only “That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue up to 8 million Options to Jeremy Steele (or his nominee) pursuant to the Control Bionics Employee Share Option Plan and on the terms
Slide 10: Resolution: Ratification of share issue
Resolution 6 is as follows: For personal use only “That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, shareholders ratify the issue of 42,624,175 shares at an issue price of 4.5c per share on 26 February 2025 to Nightingale Partners Pty Limited and Phoenix Development Fund Li
Slide 11: Resolution: Additional 10% placement capacity
Resolution 7 is as follows: For personal use only “That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue equity securities up to an additional 10% of its issued capital by way of placements over a 12-month period, on the terms and cond
Slide 12: Disclaimer
Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or
Slide 13: CEO Presentation
For personal use only CEO Presentation Jeremy Steele
Slide 14: Proven tech. Commercial traction. Global scaling.
INV ES TME NT H IGH LIG HTS Proven tech. Commercial traction. Global scaling. A validated surface electromyography (sEMG) platform delivering For personal use only real-world outcomes in communication, rehab, and sport — now expanding with global approvals, revenues, and reach. Global validation Gro
Slide 15: 2025: A breakthrough year
THE YEAR IN REVIEW 2025: A breakthrough year US HCPCS insurance code • First AAC code awarded in 13 years For personal use only HCPCS Code • US$4,300 fixed rebate for a NeuroNode • Protected IP underpins opportunity for CBL Wholesale channel open NeuroNode • NeuroNode works seamlessly with all major
Slide 16: Finance: FY25 strongest year in our history
FINANCE US pipeline is at its highest ever. Strong $1m+ AU sales pipeline remains. FY25: Strongest year in RE VE NUE (A$ m) EBITDA ($A m) our history For personal use only • FY25 operating revenue: $6.1m, up 15% YoY, mainly driven by strong US sales following the implementation of the HCPCS reimburs
Slide 17: Strategic Focus 2026
STRATEGIC FOCUS 2026 Continued focus: Grow. Diversify. Innovate. NeuroNode Only NeuroStrip Data as a driver For personal use only • US partnerships close to finalisation • Scaling production now to • Technology partnerships are a accelerate business development sign of the opportunities our • CBL is
Slide 18: Core IP & Products
CONTROL BIONICS. gege Core IP & a ak ~ Products
Slide 19: Neurotech is poised for explosive growth
MARKET OVERVIEW Neurotech is poised for explosive growth Breakthroughs in sensing, AI, and edge computing are accelerating the adoption of neural interfaces across healthcare, sport, and beyond — with EMG offering a major edge over other neurotechnologies. For personal use only DR IVERS SEGMENTS The
Slide 20: EMG vs. Other Neurotechnologies
MARKET OVERVIEW EMG vs. Other Neurotechnologies For personal use only
Slide 21: One platform. Multiple markets.
SNAPSHOT One platform. Multiple markets. Powering assistive communication, rehab and elite sport. For personal use only 1 PLATFORM 2 KEY PRODUCTS 3 KEY MARKETS 3 CUSTOMER SEGMENTS 4 REVENUE STREAMS • NeuroNode® • Augmentative and • Disabled and diseased • Hardware sales • NeuroStrip® Alternative Com
Slide 22: NeuroStrip: A game-changer with blue sky potential
PROD UCT NeuroStrip®: A game-changer with blue sky potential A world-first all-in-one accelerometer and EMG device that measures physiological data like unintentional muscle movement. For personal use only Market strategy: Enter those with the fastest, lowest- cost access with no extra approvals. ht
Slide 23: Neurobounce: World-first EMG training system
SPORTS PER FOR MANCE Neurobounce: World-first EMG training system Patent-pending system delivering explosive athletic gains in speed, power, and agility by retraining brain- to-muscle signals — with guaranteed results and a scalable royalty model. For personal use only WEARABLE WIRELESS TRAIN FOR PE
Slide 24: Athlete Profiling and return to play
SPORTS PER FOR MANCE Athlete Profiling and return to play •Real-time muscle activation mapping Provides instant sEMG feedback during training so coaches can see exactly which muscles are firing, when, and how hard — optimising technique, force production, and movement efficiency. For personal use on
Slide 25: A new kind of training. A new level of results.
SPORTS PER FOR MANCE A new kind of training. A new level of results. For personal use only “The secret to the explosive hops is not in your legs. It’s your neural pathways.” Preston Denison (NeuroBounce Program Manager, USA) https://vimeo.com/1080698667
Slide 26: Progress
CONTROL BIONICS. Progress aD |
Slide 27: New integration with Apple's Brain–Computer Interface protocol
ASSISTIVE COM MUNICATION New integration with Apple’s Brain–Computer Interface (BCI) protocol For personal use only We are now the only company in the world with a commercially available product using Apple's BCI tech. We’re already FDA and TGA-approved with established funding pathways. EVOLVING BC
Slide 28: NeuroNode wholesale: Unlocking scale in a $1B+ global market
ASSISTIVE COM MUNICATION NeuroNode® wholesale: Unlocking scale in a $1B+ global market For personal use only Our fastest near-term growth lever — now scaling in the US with HCPCS-backed wholesale partners. Global partners are expected to be announced by the end of 2025. MARKET OPPORTUNITY PROGRESS •
Slide 29: Real trials. Real gains. Real endorsements.
SPORTS PER FOR MANCE Real trials. Real gains. Real endorsements. Exceptional initial results. Growing demand. Commercial rollout in motion. For personal use only NEUROBOUNCE USA Outstanding results for first athletes with launch customer, Continued Utah Prep Academy, Princeton College and Nets on Fi
Slide 30: Rehab: Trusted by experts. Scaling with innovation.
RE HAB Rehab: Trusted by experts. Scaling with innovation. Japan’s leading stroke rehab centre adopts NeuroStrip® to provide superior outcomes for its patients. For personal use only JAPAN: STROKELAB REHAB CENTRE US & AU: REHAB Coherent Market Insights Dysphagia Management Market-& Forecast 2025-203
Slide 31: Get In Touch
Get In Touch For personal use only COMPANY I NVE ST OR RE LATI ONS JEREMY ST EELE J OE DU RA K CEO E X E C UT IV E D I RE C TO R & F OU ND E R CO NT R OL BIO NI CS LYN X A DV I SO R S js teele@c ontrolbionic s. com jo e @l y n xa d v is or s.c o m .a u +61 433 229 470 +61 414 465 582 CON TR OLBIO NI
Control Bionics — Shareholder Meeting (November 2025) on 6ix